RT Journal Article
SR Electronic
T1 Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1629
OP 1639
DO 10.21873/anticanres.14925
VO 41
IS 3
A1 MORI, SHOZO
A1 AOKI, TAKU
A1 SAKURAOKA, YUHKI
A1 SHIMIZU, TAKAYUKI
A1 YAMAGUCHI, TAKAMUNE
A1 PARK, KYUNG-HWA
A1 MATSUMOTO, TAKATSUGU
A1 SHIRAKI, TAKAYUKI
A1 ISO, YUKIHIRO
A1 KUBOTA, KEIICHI
YR 2021
UL http://ar.iiarjournals.org/content/41/3/1629.abstract
AB Background/Aim: An association between the pathological response to neoadjuvant chemotherapy (NAC) and the efficacy of adjuvant chemotherapy (AC) in patients with pancreatic ductal adenocarcinoma (PDAC) remains unknown. Patients and Methods: A total of 121 patients with PDAC who underwent a pancreatectomy between January 2013 and March 2020 were divided into two groups: an upfront surgery (UFS) group (n=42), and an NAC (gemcitabine plus S-1) group (n=79). In the NAC group, the pathological response was evaluated using the Evans classification. Results: The overall survival was significantly higher in patients with an AC relative dose intensity (RDI) ≥80% than in patients with an AC RDI <80% in the UFS, NAC-Evans IIa, and NAC-Evans IIb+III groups. However, this difference was not observed in the NAC-Evans I group. Conclusion: AC is preferable for patients with NAC-Evans IIa or IIb+III, but more effective AC regimens may be needed for NAC-Evans I patients.